• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORDIS CASHEL TRAPEASE PVCF FEM/JUG 55CM CSI; CATHETER, INTRAVASCULAR, DIAGNOSTIC

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORDIS CASHEL TRAPEASE PVCF FEM/JUG 55CM CSI; CATHETER, INTRAVASCULAR, DIAGNOSTIC Back to Search Results
Catalog Number 466P306AU
Device Problem Failure to Align (2522)
Patient Problems Embolus (1830); Occlusion (1984); Internal Organ Perforation (1987); Perforation (2001); Swelling (2091); Numbness (2415)
Event Date 11/11/2013
Event Type  Injury  
Manufacturer Narrative
As reported, the patient underwent placement of a trapease vena cava filter.The filter subsequently malfunctioned, tilted within and perforated the inferior vena cava (ivc) wall and caused injury and damages to the patient, including, but not limited to, blood clots, clotting and occlusion of the inferior vena cava (ivc).As a direct and proximate result of these malfunctions, the patient suffered injuries and damages, which require or required medical care and treatment.As a further proximate result, the patient has suffered and will continue to suffer medical expenses, pain and suffering, and other damages.The product was not returned for analysis.Additionally, as the sterile lot number was not available, device history record review could not be performed.The inferior vena cava filter is indicated for use in the prevention of recurrent pulmonary embolism (pe) via percutaneous placement in the vena cava for patients in which anticoagulants are contraindicated, anticoagulant therapy for thromboembolic disease has failed, emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced or for chronic, recurrent pulmonary embolism where anticoagulant therapy has failed, or is contraindicated.The purpose of a vena cava filter is to catch thrombus from the lower extremities as it travels along normal blood flow patterns up towards the heart.Blood clots and occlusion within the ivc does not represent a device malfunction.Clinical factors that may have influenced the event include patient, pharmacological and lesion characteristics.Without procedural films for review, the reported filter tilt and perforation of the ivc could not be confirmed.The timing and mechanism of the tilt has not been reported at this time.The brief also reported perforation of the ivc; however, a clinical conclusion could not be determined as to the cause of the event.It is unknown if the tilt contributed to the reported perforation.A review of the instructions for use notes vessel damage such as intimal tears and perforation as procedural complications related it ivc filters.Given the limited information available for review at this time, there is nothing to suggest that the reported event is related to the design and manufacturing process of the device; therefore no corrective action will be taken.Should additional information become available, the file will be updated accordingly.
 
Event Description
As reported by the legal brief, the patient underwent placement of defendants¿ trapease vena cava filter.The filter subsequently malfunctioned, tilted within and perforated the inferior vena cava (ivc) wall and caused injury and damages to the patient, including, but not limited to, blood clots, clotting and occlusion of the inferior vena cava (ivc).As a direct and proximate result of these malfunctions, the patient suffered injuries and damages, which require or required medical care and treatment.As a further proximate result, the patient has suffered and will continue to suffer medical expenses, pain and suffering, and other damages.
 
Manufacturer Narrative
The following additional information received per the medical records indicate that the filter was deployed at the l2-l3 interspace without any difficulties.The filter was placed because of history of recurrent deep venous thrombosis (dvt) and pulmonary emboli (pe).The medical records also state that the patient has a history of factor v deficiency and had a bleeding episode while on coumadin in the past.According to the information received in the patient profile from (ppf), approximately on or about one month and two days post implantation the patient now suffers from anxiety, swelling and pain in left leg, numbness in both legs, back pain, and chest pain.Patient also reports to have perforation of filter strut into organs.As reported, the patient underwent placement of a trapease inferior vena cava (ivc) filter.Per the medical records, the filter was deployed at the l2-l3 interspace without any difficulties.The filter was placed because of history of recurrent deep venous thrombosis (dvt) and pulmonary emboli (pe).The medical records also state that the patient has a history of factor v deficiency and had a bleeding episode while on coumadin in the past.The filter subsequently malfunctioned, tilted within and perforated the ivc wall causing injury and damages to the patient, including, but not limited to, blood clots, clotting and occlusion of the inferior vena cava (ivc).As a further proximate result, the patient has suffered and will continue to suffer medical expenses, pain and suffering, and other damages.According to the information received in the patient profile from (ppf), approximately one month and two days post implantation the patient now suffers from anxiety, swelling and pain in left leg, numbness in both legs, back pain, and chest pain.The patient also reports to have perforation of filter strut into organs.The filter remains implanted; thus, unavailable for analysis.The product was not returned for analysis.A review of the device history record revealed no anomalies during the manufacturing and inspection processes that can be associated with the reported complaint.The trapease vena cava filter is indicated for use in the prevention of recurrent pulmonary embolism (pe) via percutaneous placement in the vena cava for patients in which anticoagulants are contraindicated, anticoagulant therapy for thromboembolic disease has failed, emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced or for chronic, recurrent pulmonary embolism where anticoagulant therapy has failed, or is contraindicated.The purpose of a vena cava filter is to catch thrombus from the lower extremities as it travels along normal blood flow patterns up towards the heart.Without procedural films for review, the filter tilt reported could not be confirmed.Additionally, the timing and mechanism of the filter tilt is unknown.Ivc filter tilt has been associated with the anatomy of the vessel, specifically asymmetry and tortuousness.It was also reported that there was perforation of the ivc; however, a clinical conclusion could not be determined as to the cause of the event.It is unknown if the tilt contributed to the reported perforation.A review of the instructions for use notes vessel damage such as intimal tears and perforation as procedural complications related it ivc filters.Blood clots, clotting and occlusive thrombosis within the filter and vasculature do not represent a device malfunction.Anxiety, pain, numbness and swelling of the lower extremities do not represent a device malfunction and may be related to underlying patient related issues.Clinical factors that may have influenced the event include patient, pharmacological and lesion characteristics.Without procedural films or images for review the reported event(s) could not be confirmed.Given the limited information available for review at this time, there is nothing to suggest that the reported events are related to the design and manufacturing process of the device; therefore, no corrective action will be taken.Should additional information become available, the file will be updated accordingly.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRAPEASE PVCF FEM/JUG 55CM CSI
Type of Device
CATHETER, INTRAVASCULAR, DIAGNOSTIC
Manufacturer (Section D)
CORDIS CASHEL
cahir road
cashel, co. tipperary
EI 
MDR Report Key7273562
MDR Text Key100177567
Report Number1016427-2018-01176
Device Sequence Number1
Product Code DQO
Combination Product (y/n)N
PMA/PMN Number
K020316
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type other
Type of Report Initial,Followup
Report Date 03/29/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date04/30/2016
Device Catalogue Number466P306AU
Device Lot Number15876220
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 01/19/2018
Initial Date FDA Received02/15/2018
Supplement Dates Manufacturer Received03/16/2018
Supplement Dates FDA Received03/29/2018
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
UNKNOWN GUIDEWIRE
Patient Outcome(s) Life Threatening;
Patient Age49 YR
Patient Weight94
-
-